anti-Udp-N-Acetyl-alpha-D-Galactosamine:polypeptide N-Acetylgalactosaminyltransferase 1 (GalNAc-T1) (Galnt1) Antibodies

Mouse (Murine) Udp-N-Acetyl-alpha-D-Galactosamine:polypeptide N-Acetylgalactosaminyltransferase 1 (GalNAc-T1) (Galnt1) interaction partners

1. Study show that in Galnt1 null mouse, there is compromised cardiac function that mimics human congenital heart disease suggesting that Galnt1 expression is required for normal heart valve development.

2. The GALNT1 is the glycosyltransferase (show GTDC2 Antibodies) enzyme family covering a single known glycosidic linkage.

3. Polypeptide GalNAcT (show B4GALNT1 Antibodies)-1 plays a predominant role in leukocyte recruitment in vivo by attaching functionally relevant O-linked glycans to L-selectin (show SELL Antibodies) ligands.

4. Growth factor stimulation regulates O-glycosylation initiation in a Src (show SRC Antibodies)-dependent fashion by GalNac-T (show B4GALNT1 Antibodies) redistribution from golgi to the endoplasmic reticulum.

5. ppGalNAcT-1 to be indispensable for O-glycosylation at specific sites of the bone glycoproteins OPN (show SPP1 Antibodies) and BSP (show KLK6 Antibodies).

Human Udp-N-Acetyl-alpha-D-Galactosamine:polypeptide N-Acetylgalactosaminyltransferase 1 (GalNAc-T1) (Galnt1) interaction partners

1. We have elucidated a novel miR (show MLXIP Antibodies)-30-GALNT1/2 axis whose dysregulation increases the proportion of inactive proBNP secreted by the heart and impairs the compensatory actions of BNP (show BNC2 Antibodies) during the progression of heart failure.

2. the GalNAc-T13 (show GALNT13 Antibodies) isoform is predicted to function similarly to GalNAc-T1 against peptide substrates in vivo, in contrast to a prior report, but is unique by being selectively expressed in the brain.

3. Expression of GALNT3 (show GALNT3 Antibodies) was reduced in CAD (show CAD Antibodies) patients, and down regulation of GALNT3 (show GALNT3 Antibodies) contributed to endothelial injury by promoting apoptosis and up-regulating the expression of MMP-2 (show MMP2 Antibodies) and MMP-14 (show MMP14 Antibodies) genes via p38 MAPK (show MAPK14 Antibodies) activation.

4. appears to be responsive to the inhibition of GALNT1 and SHH (show SHH Antibodies) signaling

5. Study demonstrates that down-regulation of GALNT1 is sufficient to suppress malignant phenotype of HCC (show FAM126A Antibodies) cells by decreasing EGFR (show EGFR Antibodies) signaling.

6. The GALNT1 is the glycosyltransferase (show GTDC2 Antibodies) enzyme family covering a single known glycosidic linkage.

7. Utilizing unnatural glycopeptide substrates for GalNAc-T3 we demonstrated that the GalNAc-specific sugar recognition of the lectin domain regulates further glycosylation.

8. Growth factor stimulation regulates O-glycosylation initiation in a Src (show SRC Antibodies)-dependent fashion by GalNac-T (show B4GALNT1 Antibodies) redistribution from golgi to the endoplasmic reticulum.

9. the present analysis fails to replicate an earlier reported association of a GALNT1 variant with risk of ovarian cancer

10. First simultaneous kinetic description of O-glycosylation events by recombinant UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (show B4GALNT2 Antibodies) I at all putative O-glycosylation sites within human mucin (show SLC13A2 Antibodies) MUC1 (show MUC1 Antibodies) containing 5 tandem repeats.